Charcot-Marie-Tooth disease

What is Charcot-Marie-Tooth disease?

Charcot-Marie-Tooth disease (CMT), also known as hereditary motor and sensory neuropathy (HMSN), is a group of inherited disorders that affect the peripheral nerves responsible for muscle movement and sensation. Named after the three physicians who first described it in 1886, CMT causes progressive weakness and sensory loss, primarily in the hands and feet. With a prevalence of approximately 1 in 2,500 people, it is the most common inherited neurological disorder affecting the peripheral nervous system. While CMT is a lifelong condition that typically worsens over time, many people with the disease lead active, fulfilling lives with appropriate management and support.

Key statistics

Symptoms

Common symptoms include: pes cavus (high-arched feet), hammer toes, stork-leg appearance, foot drop, muscle weakness, sensory loss, balance problems, fatigue, hand weakness, scoliosis.

CMT symptoms typically begin in the feet and legs before progressing to the hands and arms. Early signs often include difficulty walking, frequent tripping or falling, and problems with balance. The characteristic “stork-leg” appearance develops as muscles in the lower legs waste away, creating a distinctive inverted bottle shape where the upper legs remain normal while the calves become thin.

Foot deformities are hallmark features of CMT. Pes cavus, or abnormally high foot arches, develops alongside hammer toes and claw toes. These changes alter the foot’s shape and function, making walking more difficult and increasing the risk of ankle sprains. Foot drop, where patients cannot lift the front part of their foot, causes a distinctive high-stepping gait as individuals compensate by lifting their legs higher.

Submit Your Paper

As the condition progresses, hand weakness may develop, affecting fine motor skills like writing, buttoning clothes, or opening jars. Sensory symptoms include reduced ability to feel temperature, vibration, and pain, particularly in the hands and feet. Many patients experience chronic fatigue, which can be more limiting than the physical weakness itself.

Causes and risk factors

CMT is caused by mutations in genes that affect the structure and function of peripheral nerves. More than 100 different genes have been associated with various forms of CMT, with the most common being PMP22 and MFN2. The PMP22 gene accounts for approximately 70% of CMT cases, while MFN2 mutations are responsible for many severe early-onset forms.

The disease follows multiple inheritance patterns. Autosomal dominant forms (CMT1 and CMT2) are most common, meaning only one copy of the mutated gene from either parent is needed to cause the disease. Autosomal recessive forms (CMT4) require two copies of the mutated gene, one from each parent. X-linked forms (CMTX) are carried on the X chromosome and typically affect males more severely than females.

The primary risk factor for CMT is having a family history of the condition. However, approximately 10-20% of cases result from new (de novo) mutations, meaning they occur in individuals with no family history of the disease. Advanced parental age may slightly increase the risk of de novo mutations.

Prevention

As CMT is an inherited genetic condition, it cannot be prevented through lifestyle modifications or environmental interventions. However, genetic counseling and testing offer valuable tools for family planning decisions. Carrier testing can identify individuals who carry one copy of a recessive CMT gene mutation, while diagnostic genetic testing can confirm the presence of CMT in symptomatic individuals.

Preimplantation genetic diagnosis (PGD) is available for couples at risk of having a child with CMT, allowing genetic testing of embryos during in vitro fertilization procedures. Prenatal testing through chorionic villus sampling or amniocentesis can detect CMT mutations during pregnancy, though these procedures carry small risks and require careful consideration with genetic counselors.

Early recognition and intervention can help prevent complications and optimize outcomes, making awareness of family history and genetic counseling important preventive measures for families affected by CMT.

Complications

Without proper management, CMT can lead to several significant complications that impact mobility and quality of life. Progressive muscle weakness may result in increased fall risk and potential injuries from trips and ankle sprains. Foot deformities often worsen over time, leading to pressure sores, calluses, and difficulty finding properly fitting footwear.

Scoliosis (spinal curvature) develops in approximately 10-30% of individuals with CMT, particularly in more severe forms. Respiratory complications may occur in severe cases due to weakness of breathing muscles, though this is uncommon in typical CMT forms.

Chronic pain can develop from muscle imbalances, joint stress, and nerve dysfunction. Fatigue often becomes a limiting factor, sometimes more so than muscle weakness itself. Social and psychological complications may arise from physical limitations, altered appearance, and the challenges of living with a progressive condition.

Contractures (permanent shortening of muscles and tendons) may develop without proper stretching and physical therapy, further limiting mobility and function. Early intervention with appropriate therapies can prevent or minimize many of these complications.

Diagnosis

CMT diagnosis involves a comprehensive evaluation combining clinical assessment, family history, neurological testing, and genetic analysis. The diagnostic journey often begins when patients or parents notice walking difficulties, frequent falls, or foot deformities.

Nerve conduction studies and electromyography (EMG) are essential diagnostic tools that measure how well nerves conduct electrical signals and assess muscle function. These tests can distinguish between demyelinating forms (CMT1) where nerve insulation is damaged, and axonal forms (CMT2) where nerve fibers themselves are affected.

Genetic testing has become the gold standard for CMT diagnosis, with comprehensive panels now available that can test for mutations in multiple CMT-associated genes simultaneously. Single gene testing may be performed when clinical features suggest specific CMT subtypes.

Additional diagnostic tools include nerve biopsy (rarely needed now due to genetic testing), magnetic resonance imaging (MRI) to assess muscle changes, and specialized neurological examinations to evaluate reflexes, sensation, and muscle strength. Family history assessment and examination of relatives may provide crucial diagnostic clues.

Treatment

Currently, no cure exists for CMT, but comprehensive management can significantly improve symptoms and quality of life. Treatment focuses on maintaining function, preventing complications, and addressing specific symptoms.

Physical therapy forms the cornerstone of CMT management, emphasizing strengthening exercises for unaffected muscles, stretching to prevent contractures, and balance training to reduce fall risk. Occupational therapy helps patients adapt daily activities and may recommend assistive devices for hand function.

Orthotic devices, particularly ankle-foot orthoses (AFOs), can dramatically improve walking ability by addressing foot drop and providing ankle stability. Custom-fitted shoes or shoe modifications accommodate foot deformities and reduce pressure points.

Pain management may involve gabapentin, pregabalin, or duloxetine for neuropathic pain. Fatigue management strategies include energy conservation techniques and, in some cases, modafinil.

Surgical interventions may be necessary for severe foot deformities, scoliosis, or carpal tunnel syndrome. Common procedures include tendon transfers, osteotomies to correct bone alignment, and arthrodesis (joint fusion) for stability.

Prognosis

The prognosis for CMT varies significantly depending on the specific genetic subtype and severity of symptoms. Most individuals with CMT have a normal or near-normal life expectancy, and many maintain independent living throughout their lives.

CMT1A, the most common form, typically progresses slowly with symptoms beginning in childhood or adolescence. Many patients remain ambulatory throughout their lives, though some may eventually require wheelchairs for longer distances. Hand function usually remains adequate for most daily activities.

More severe forms like CMT4 or certain CMT2 subtypes may cause earlier onset of symptoms and faster progression, potentially leading to wheelchair dependence and more significant disability. However, even in severe forms, intellectual function remains normal.

Early diagnosis and appropriate management significantly improve outcomes. Patients who receive timely physical therapy, appropriate orthotics, and comprehensive care typically maintain better function and experience fewer complications than those without proper management.

Quality of life

Living well with CMT requires adaptive strategies and supportive care, but many individuals lead fulfilling, active lives. Regular low-impact exercise like swimming, cycling, or walking helps maintain strength and cardiovascular health without overexerting affected muscles.

Workplace accommodations may include ergonomic equipment, modified duties, or flexible schedules to manage fatigue. Many successful professionals across all fields have CMT, demonstrating that the condition need not limit career aspirations.

Home modifications such as grab bars, ramps, and good lighting can enhance safety and independence. Energy conservation techniques help manage fatigue by prioritizing activities and planning rest periods.

Mental health support is crucial, as living with a progressive condition can be challenging. Counseling, support groups, and connecting with others who have CMT provide valuable emotional support and practical advice. Maintaining social connections and hobbies adapted to current abilities contributes significantly to overall well-being.

Pregnancy and fertility

CMT typically does not affect fertility in men or women. However, pregnancy may temporarily worsen CMT symptoms due to weight gain, fluid retention, and changes in center of gravity that can affect balance and mobility.

Genetic counseling before conception is essential to understand inheritance risks. For autosomal dominant forms, each child has a 50% chance of inheriting the condition. For recessive forms, risk depends on whether the partner is also a carrier.

Most medications used for CMT symptoms are relatively safe during pregnancy, though adjustments may be necessary. Gabapentin and pregabalin require careful risk-benefit assessment during pregnancy.

Physical therapy becomes particularly important during pregnancy to address changing body mechanics and maintain mobility. Proper footwear and orthotic adjustments may be needed as pregnancy progresses.

Children

CMT in children often presents differently than in adults, with symptoms sometimes subtle and easily overlooked. Parents may notice frequent tripping, difficulty with sports, or fatigue after physical activities. Some children develop learning difficulties related to fine motor skills rather than intellectual problems.

Early intervention with pediatric physical and occupational therapy can significantly impact long-term outcomes. Children may need educational accommodations such as modified physical education, extra time for writing tasks, or assistive technology.

Psychological support helps children and families cope with diagnosis and adapt to living with a chronic condition. Maintaining age-appropriate activities and encouraging participation in adapted sports or activities supports normal development and self-esteem.

Regular monitoring by pediatric neurologists ensures appropriate management adjustments as children grow and develop.

When to see a doctor

Seek medical evaluation if you or your child experience frequent falls, difficulty walking, foot deformities, or progressive weakness in hands or feet. Early signs warranting medical attention include high-arched feet, hammer toes, muscle wasting in the lower legs, or family history of similar symptoms.

Urgent medical care is rarely needed for CMT itself, but seek immediate attention for severe injuries from falls, sudden worsening of symptoms, or respiratory difficulties in severe forms.

Regular follow-up with neurologists, physical therapists, and other specialists helps monitor progression and adjust treatments. Annual evaluations allow for timely interventions and complication prevention.

Regional context

Specific prevalence data for CMT in the Caucasus region (Georgia, Armenia, Azerbaijan) and Eastern Mediterranean is limited in published literature. However, the condition occurs across all ethnic groups and geographical regions at approximately similar rates to the global prevalence of 1 in 2,500.

Certain populations may have higher frequencies of specific CMT genetic subtypes due to founder effects or consanguineous marriages, which increase the likelihood of recessive forms. The Global Medical Journal welcomes contributions from regional researchers and clinicians who can provide insights into local CMT prevalence, genetic patterns, and healthcare access challenges in these regions.

Research and clinical trials

CMT research has accelerated dramatically in recent years, with multiple therapeutic approaches in development. Gene therapy trials are investigating treatments for specific CMT subtypes, with promising early results for CMT1A using antisense oligonucleotides to reduce PMP22 protein levels.

Small molecule drugs targeting various aspects of CMT pathophysiology are in clinical trials. These include compounds aimed at improving mitochondrial function, reducing oxidative stress, and promoting nerve regeneration. Ascorbic acid (vitamin C) has shown mixed results in clinical trials for CMT1A.

Stem cell therapies and nerve regeneration approaches represent emerging research areas. Advanced gene editing techniques like CRISPR offer potential future therapeutic avenues.

Current clinical trials can be found at ClinicalTrials.gov by searching for “Charcot-Marie-Tooth.” The Charcot-Marie-Tooth Association (CMTA) maintains updated information about ongoing research and trial opportunities for patients.

Frequently asked questions

Is CMT inherited and will I pass it to my children?

CMT inheritance patterns vary by type. Dominant forms have a 50% chance of transmission to each child, while recessive forms only occur when both parents carry the gene. Genetic counseling can provide personalized risk assessments and family planning guidance.

Will CMT put me in a wheelchair?

Most people with CMT remain ambulatory throughout their lives, though some may use wheelchairs for longer distances. The progression varies greatly between individuals and CMT subtypes. Early intervention and proper management can help maintain mobility longer.

Can exercise make CMT worse?

Appropriate exercise generally benefits CMT patients by maintaining strength and cardiovascular health. Low-impact activities like swimming and cycling are particularly beneficial. Avoid overexertion and work with physical therapists to develop safe exercise programs.

Are there any medications that can worsen CMT?

Certain medications can potentially worsen CMT symptoms, including some chemotherapy drugs, high-dose vitamins B6, and certain antibiotics. Always inform healthcare providers about your CMT diagnosis before starting new medications.

Can CMT affect my thinking or intelligence?

CMT affects only peripheral nerves and does not impact intelligence or cognitive function. Any learning difficulties typically relate to fine motor skills rather than intellectual capacity. Most people with CMT have normal cognitive abilities.

Support and resources

• Charcot-Marie-Tooth Association (CMTA): https://cmtausa.org
• Orphanet: https://orpha.net
• National Organization for Rare Disorders (NORD): https://rarediseases.org
• EURORDIS (European Rare Disease Organisation): https://eurordis.org
• Muscular Dystrophy Association: https://mda.org
• CMT Research Foundation: https://cmtrf.org

Related conditions

Hereditary spastic paraplegia
Muscular dystrophy
Diabetic neuropathy
Guillain-Barré syndrome
Friedreich ataxia

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.